247 related articles for article (PubMed ID: 26263848)
1. Professional risks when carrying out cytoreductive surgery for peritoneal malignancy with hyperthermic intraperitoneal chemotherapy (HIPEC): A French multicentric survey.
Ferron G; Simon L; Guyon F; Glehen O; Goere D; Elias D; Pocard M; Gladieff L; Bereder JM; Brigand C; Classe JM; Guilloit JM; Quenet F; Abboud K; Arvieux C; Bibeau F; De Chaisemartin C; Delroeux D; Durand-Fontanier S; Goasguen N; Gouthi L; Heyd B; Kianmanesh R; Leblanc E; Loi V; Lorimier G; Marchal F; Mariani P; Mariette C; Meeus P; Msika S; Ortega-Deballon P; Paineau J; Pezet D; Piessen G; Pirro N; Pomel C; Porcheron J; Pourcher G; Rat P; Regimbeau JM; Sabbagh C; Thibaudeau E; Torrent JJ; Tougeron D; Tuech JJ; Zinzindohoue F; Lundberg P; Herin F; Villeneuve L;
Eur J Surg Oncol; 2015 Oct; 41(10):1361-7. PubMed ID: 26263848
[TBL] [Abstract][Full Text] [Related]
2. Operating personnel safety during the administration of Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Kyriazanos I; Kalles V; Stefanopoulos A; Spiliotis J; Mohamed F
Surg Oncol; 2016 Sep; 25(3):308-14. PubMed ID: 27566037
[TBL] [Abstract][Full Text] [Related]
3. Current practice in cytoreductive surgery and HIPEC for metastatic peritoneal disease: Spanish multicentric survey.
Morales-Soriano R; Esteve-Pérez N; Segura-Sampedro JJ; Cascales-Campos P; Barrios P;
Eur J Surg Oncol; 2018 Feb; 44(2):228-236. PubMed ID: 29242018
[
